Archives

• 

  SMART-MD Journal of Precision Medicine Vol 2, No 3, (Summer) 2025

  Vol. 2 No. 3 (2025)

  SMART-MD Journal of Precision Medicine (JPM) is designed to bring world class expertise to practicing physicians, physician extenders, genetic counselors and trainees. 

  This issue includes an outstanding papers on:

  Type 3c Diabetes from the perspective of endocrinology (Al-Bahadili et al.). 

  Gene variant calling has become a major issue in Precision Medicine, and three papers address the issue and examples of why new considerations are needed:   Editorial - Adding a "Predisposing" variant is addressed (Whitcomb).  Celiac disease and "missing genetics" is explained (Quigley)  Polygenic risk scores (PRS) and their use for the land-scape effects of low-risk single nucleotide variants (SNVs) (Greer & DeFrancesco Oranburg). 

  --> Bookmark this Page and Papers that you want.

  --> Alert colleagues about this issue and the contents.

  Thank you for reading SMART-MD JPM.

• 

  SMART-MD Journal of Precision Medicine (Spring 2025): Diabetes Melitus

  Vol. 2 No. 2 (2025)

  Diabetes mellitus is a metabolic syndrome that is much more complex than simple type 1 or type 2.  This issue SMART-MD JPM, with Guest Editor Melena Bellin MD, highlights the insights of leading experts on subtypes of diabetes such as MODYs and monogenic diabetes, cystic fibrosis-related diabetes (CFRD), early detection and management of type 1 diabetes in adults and use of Teplizumab-mzwv in children. Updates on imaging findings in T1DM and state-of-the art in automated insulin delivery are also presented. These insights contribute greatly to delivery of the right treatment to the right patient at the right time - ie the promise of precision medicine. 

• 

  SMART-MD Journal of Precision Medicine (Winter 2025)

  Vol. 2 No. 1 (2025)

  Winter 2025 Issue Spotlight: Pancreatic Diseases

  This edition features a SMART-Approach by Drs Paul and Brand on guidelines on Surveillance for Pancreatic Cancer as a clinical decision support tool (CDS) for physicians.   A more detailed SMART Medical Review on expert management of exocrine pancreatic insufficiency (EPI) with pancreatic enzyme replacement therapy (PERT) is given by expert John Lieb II.   Details on SPINK1 genetic analysis is provided in a SMART-System Review.       

  Bookmark this issue and share it with your network!

  Let's make precision medicine the forefront of pancreatic cancer detection and treatment from the outset.    

  Cover Image:  Three-dimensional structure of a serine protease similar to trypsin (i.e. chymotrypsin) interacting with SPINK1 (from PMID:1870127 visualized with NCBI Structure Summary MMDB: 1CGJ).  The image includes the protease (left) and SPINK1 (right) with structural subchains highlighted in Rainbow color. See Waqar et al for information on the pathophysiology of SPINK1 variants in pancreatitis.  

• 

  SMART-MD Journal of Precision Medicine (Spring 2024)

  Vol. 1 No. 1 (2024)

  Special Issue: Pancreatic diseases.

  Guest editor: C Mel Wilcox MD

  Welcome to SMART-MD Journal of Precision Medicine. See the Editorial and bookmark this site!  

  Precision Medicine for Complex Disorders is an emerging discipline that considers the mix of genes, environment, and biomarkers to explain symptoms, causes, outcomes, and treatment choices for individual patients. Healthcare providers require clinical decision support (CDS) based on expert insights tailored to similar patient precision medicine profiles.

  SMART-MD JPM kicks off with pancreatic diseases, spotlighting chronic pancreatitis as a case study for precision medicine. It features an article on diagnosis of chronic pancreatitis by Professors David C Whitcomb MD PhD  and Dhiraj Yadav MD MPH, and another on pain management in pancreatitis by Prof. Vikesh Singh from Johns Hopkins.

  Biomarkers in Pancreatic Cancer: CA 19-9 serves as a biomarker for pancreatic adenocarcinoma (PDAC). An expert review discusses the biology, genetics, and clinical application of CA 19-9 and CEA for managing PDAC patients.

  Welcome to SMART-MD Journal of Precision Medicine

• 

  SMART-MD Journal of Precision Medicine (Fall 2024)

  Vol. 1 No. 3 (2024)

  Fall 2024 Issue Spotlight: Pancreatic Cancer

  This edition emphasizes the Early Diagnosis of Pancreatic Cancer, featuring articles on differentiating Autoimmune Pancreatitis (AIP) from other conditions with similar early signs and symptoms, and pinpointing PDAC High-Risk Individuals (HRI-C) through a blend of genetic risk factors and new biomarkers for early signs of Pancreatic Ductal Adenocarcinoma (PDAC).

  For treatment, the focus is on chemotherapy regimens like FOLFIRINOX, with discussions on the high chemotoxicity linked to genetic variations in drug metabolism, particularly for irinotecan and 5-FU. Two standout papers delve into pharmacogenetics.

  Bookmark this issue and share it with your network! Let's make precision medicine the forefront of pancreatic cancer detection and treatment from the outset.
• 

  SMART-MD Journal of Precision Medicine (Summer 2024)

  Vol. 1 No. 2 (2024)

  Summer 2024 Issue Spotlight: Pancreatic Diseases and Pharmacogenetics

  Precision Medicine tailors treatment to match an individual's genetics, risk factors, and biomarkers, ensuring the correct treatment, dose, and timing, including pharmacogenetics for drug dosing.

  Acute and Chronic Pancreatitis: Biomarkers in acute pancreatitis (AP) require quick decisions within 24 hours.  The consensus article by Lee et al. gives clinical decision support guidance for early management of AP. For chronic pancreatitis, C. Mel Wilcox discusses the use of fecal elastase (FE1) for accurately diagnosing EPI, while Andrea Geisz explains interpreting complex PRSS1 genetic results.

  Pharmacogenetics (PGx): Essential across all medical treatments, PGx involves tailoring treatments based on genetic makeup. Experts Yang and Luzum highlight PGx considerations for beta-blockers, offering practical applications.